ELP depots are used for the treatment of diabetes type II by the delivery of glucagon-like peptide-1 (GLP-1), an incretin peptide which controls the release of insulin from pancreatic beta-cells. The gene discussed is GCG; the disease is type 2 diabetes mellitus.